Early detection is the "Holy Grail" in cancer research and treatment.

Certain pieces of DNA called ctDNA or circulating tumor DNA, are shed from the tumors into the bloodstream allowing for our new non-invasive cancer screen for advanced solid tumors. Traditional tissue biopsy techniques can be extremely difficult, risky, painful and expensive to obtain. With liquid biopsy, a blood test can detect genetic mutations associated with cell-free DNA allowing our scientists to affirm the cancer origin.

PM Solutions offers the only clinically validated comprehensive liquid biopsy testing

73 genes for mutations, indels, amplifications, and fusions achieving a specificity of 99.9999%. This includes every guideline-recommended somatic alteration.

Our liquid biopsy test is indicated for all solid tumors including, but not limited to, the following:

  • breast cancer
  • colorectal cancer
  • lung cancer
  • stomach cancer
  • metastatic disease
  • pancreatic cancer
  • prostate cancer
  • brain tumors including gliomas

Contraindications for liquid biopsy may include stage I or stage II cancers and blood (hematologic) malignancies such as leukemias.

Our tests are ideal for helping clinicians detect recurrent or persistent disease.

In addition, once cell free DNA is analyzed we can further help guide future drug therapies. Liquid biopsy can also identify mutations that are linked to treatment resistance that even a normal tissue biopsy was unable to detect.

These tests are covered by most commercial insurances

So what does this mean for physicians and patients?

  • By using liquid biopsy you may discover mutations in the ctDNA that have been proven to resist the standard drug therapies and provide a clinically intelligent decision on which drugs will not work for your specific cancer.

  • This helps to eliminate the trial and error method many physicians are plagued with.